Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Cellophil (TM) is particularly designed for optical lenses, drug delivery and also may be used as additive for food and cosmetics or as fiber for fabrics. More
Researchers at the University of Western Ontario have developed a Pulmonary Drug Delivery Technology Suite comprised of two innovative inventions for the precision measurement and dispensing of micro fine, dry powders. More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
Cripto-1 expression increases the expression of TNF-alpha in CD4+ T cells in tissues affected by chronic inflammatory disease. More
The University of Edinburgh has perfected a genetic engineering strategy in mouse embryonic stem cells to replace large regions of mouse chromosomal sequences (>100kb) with the corresponding human syntenic region. More
1,2,4-benzothiadiazine derivatives useful for the treatment of endocrinological system diseases such as hyperinsulinaemia and diabetes. More
This TACE inhibitory protein could be used as a new therapeutic agent against chronic inflammatory diseases that are mediated by TNF-alpha. More
Gastro Retentive Drug Delivery System More
The matrix consists of two polysaccharides, xanthan and locus More
A fractionated herbal extract (STD052) demonstrating cholesterol/triglyceride lowering properties, purified down to a single active compound (STD07), a potential drug candidate for the treatment of GI disorders. More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Appendicitis
- Cholangitis, sclerosing
- Colitis
- Colitis, ulcerative
- Constipation
- Crohn's disease
- Diarrhea
- Dyspepsia
- Electrolyte replacement
- Emesis
- Emesis, motion
- Esophagitis
- Flatulence
- Food poisoning
- Gastritis
- Gastroesophageal reflux disorder
- Gastrointestinal (other)
- Gastrointestinal secretions
- Gastroprokinetic
- Helicobacter pylori
- Inflammatory bowel disease
- Irritable bowel syndrome
- Nausea
- Pancreatitis
- Ulcer
- Ulcer, gastric
- Ulcer, gastroduodenal
- Ulcer, peptic
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us